Eledon Pharmaceuticals Inc.

8.04-0.7500-8.53%Vol 151.10K1Y Perf -10.68%
Jun 14th, 2021 16:00 DELAYED
BID7.98 ASK8.05
Open8.82 Previous Close8.79
Pre-Market- After-Market-
 - -  - -%
Target Price
32.60 
Analyst Rating
— — 0.00
Potential %
305.47 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap115.03M 
Earnings Rating
Price Range Ratio 52W %
8.88 
Earnings Date
13th May 2021

Today's Price Range

7.908.85

52W Range

6.1627.32

5 Year PE Ratio Range

-0.6000-0.6000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.25%
1 Month
-9.15%
3 Months
-42.32%
6 Months
-55.65%
1 Year
-10.68%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ELDN8.04-0.7500-8.53
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.37-0.57-54.05
Q03 2020-1.64-3.91-138.41
Q02 2020--2.70-
Q01 2020--8.45-
Q04 2019-4.14-3.2421.74
Q03 2019--3.96-
Q02 2019--6.30-
Q01 2019--0.52-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.37
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume151.10K
Shares Outstanding14.31M
Trades Count1.07K
Dollar Volume1.51M
Avg. Volume58.16K
Avg. Weekly Volume98.98K
Avg. Monthly Volume50.08K
Avg. Quarterly Volume50.61K

Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) stock closed at 8.04 per share at the end of the most recent trading day (a -8.53% change compared to the prior day closing price) with a volume of 152.71K shares and market capitalization of 115.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Eledon Pharmaceuticals Inc. CEO is David-Alexandre C. Gros.

The one-year performance of Eledon Pharmaceuticals Inc. stock is -10.68%, while year-to-date (YTD) performance is -47.79%. ELDN stock has a five-year performance of %. Its 52-week range is between 6.16 and 27.32, which gives ELDN stock a 52-week price range ratio of 8.88%

Eledon Pharmaceuticals Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.68, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.43%, a ROC of -23.62% and a ROE of -23.56%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Eledon Pharmaceuticals Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.37 for the next earnings report. Eledon Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Eledon Pharmaceuticals Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Eledon Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eledon Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eledon Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.42, ATR14 : 0.69, CCI20 : -33.73, Chaikin Money Flow : -0.28, MACD : -0.35, Money Flow Index : 30.13, ROC : -2.22, RSI : 45.52, STOCH (14,3) : 48.13, STOCH RSI : 1.00, UO : 38.97, Williams %R : -51.87), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eledon Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

CEO: David-Alexandre C. Gros

Telephone: +1 949 238-8090

Address: 19900 MacArthur Boulevard, Irvine 92612, CA, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

50%50%

News

Stocktwits